Loading company…
Schlieren, Switzerland biotech developing antibody therapies to promote nerve growth and repair after spinal cord injury.
Founded in 2015 and headquartered in Schlieren, Switzerland, NOVAGO Therapeutics AG was co-founded by Prof. Martin E. Schwab and Prof. Roger Nitsch, and Dr. Stefan Moese is CEO. It develops human antibody therapeutics for nerve growth and regeneration, focused on spinal cord injury and diabetic retinopathy. Its lead product, NG004, blocks the Nogo-A receptor. In August 2026 the company raised CHF 24 million in Series B funding co-led by Neurimmune AG and Pureos Bioventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in